Table 3 Impacts of gene mutations on relapse free and overall survival in 37 AML patients receiving IDAC and HiDAC consolidation
Factors | Median RFS | 1y-RFS | 3y-RFS | 5y-RFS | Median OS | 1y-OS | 3y-OS | 5y-OS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDAC (Mo) | p | HiDAC (Mo) | p | IDAC (%) | HiDAC (%) | IDAC (%) | HiDAC (%) | IDAC (%) | HiDAC (%) | IDAC (Mo) | p | HiDAC (Mo) | p | IDAC (%) | HiDAC (%) | IDAC (%) | HiDAC (%) | IDAC (%) | HiDAC (%) | |
Gene mutation | ||||||||||||||||||||
 FLT3-ITD | 15 | 0.51 | – | 0.640 | 100 | – | 0 | – | 0 | – | 16 | 0.206 | – | 0.982 | 100 | – | 0 | – | 0 | – |
 NPM1 | 51 | – | 71 | – | 71 | – | 36 | – | NR | – | 100 | – | 83 | – | 83 | – | ||||
 FLT3-ITD and NPM1 | 22 | – | 100 | – | 0 | – | 0 | – | 23 | – | 100 | – | 0 | – | 0 | – | ||||
 CEBPA | 13 | 12 | 100 | 50 | NA | NA | NA | NA | 19 | 23 | 100 | 100 | NA | NA | NA | NA | ||||
 No mutation | 11 | 11 | 50 | 50 | 29 | 38 | 0 | 38 | 22 | 31 | 86 | 90 | 27 | 36 | NA | 36 | ||||
FLT3-ITD mutation | ||||||||||||||||||||
 Yes | 15 | 0.813 | – | – | 100 | – | 0 | – | 0 | – | 16 | 0.192 | – | – | 100 | – | 0 | – | 0 | – |
 No | 14 | 12 | 61 | 50 | 42 | 40 | 14 | 40 | 30 | 31 | 91 | 92 | 40 | 35 | 40 | 35 | ||||
NPM1 mutation | ||||||||||||||||||||
 Yes | 51 | 0.116 | – | – | 45 | – | 56 | – | 28 | – | NR | 0.116 | – | – | 100 | – | 69 | – | 69 | – |
 No | 14 | 12 | 59 | 50 | 29 | 40 | 0 | 40 | 22 | 31 | 88 | 92 | 25 | 35 | 25 | 35 | ||||
CEBPA mutation | ||||||||||||||||||||
 Yes | 13 | 0.777 | 12 | 0.64 | 61 | 50 | 37 | NA | NA | NA | 19 | 0.797 | 23 | 0.982 | 100 | 100 | NA | NA | NA | NA |
 No | 14 | 11 | 50 | 50 | NA | 38 | 12 | 38 | 25 | 31 | 91 | 90 | 37 | 36 | 37 | 36 | ||||